Antioxidants and Hypoxia in Cancer Therapy
A special issue of Antioxidants (ISSN 2076-3921). This special issue belongs to the section "Health Outcomes of Antioxidants and Oxidative Stress".
Deadline for manuscript submissions: closed (5 July 2023) | Viewed by 2832
Special Issue Editor
Interests: oncology; epigenetics; miRNA; natural products; cancer; antioxidants; apoptosis
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
In order to stop free radicals from causing harm, antioxidants interact with them and neutralize them. Another name for antioxidants is “free radical scavengers”. Some of the antioxidants that the body uses to combat free radicals are produced by it. Endogenous antioxidants is the name given to these compounds. However, the body must obtain the remaining antioxidants it requires from external (exogenous) sources, primarily through diet. Antioxidants appear to be able to: I) reduce the risk of cancer formation by squelching ROS involved in cancer initiation and progression; and II) help cancer and precancer cells to survive once the malignant transformation has already taken place. Antioxidants have been shown to help cancer to develop, hinder cancer treatment by lowering patient survival rates, and vice versa. However, there are also reports of antioxidants having a positive impact on cancer treatment.
Cancer hypoxia, which is acknowledged as one of the most significant characteristics of cancer, affects processes related to metabolism, gene expression, and ultimately tumor biology. Deficient or improper vascularization, as well as systemic hypoxia of the patient (often brought on by anemia), are the main causes of cancer hypoxia. Hypoxia-induced transcription factors then cause a special type of genetic reprogramming (HIF). However, independent of oxygen supply, constitutive activation of oncogene-driven signaling pathways may also activate hypoxia signaling. The angiogenic phenotype, a novel metabolic profile, and the immunosuppressive microenvironment are the results of HIF activation in tumors. Two of the main causes of therapy resistance are cancer hypoxia and the induced adaptation mechanisms. It is clear that cancer patients have an unmet need for targeted hypoxia therapies to enhance the effectiveness of various anticancer therapeutic modalities. Due to the recent approval of the first-in-class HIF2 inhibitor, the case has been opened. The hypoxia inducible transcription factors HIF1a, HIF2a, and HIF3a serve as the central node where hypoxia signaling converges. On the basis of research on various hereditary cancer syndromes, a role for HIFa proteins, particularly HIF1a and HIF2a, in the beginning of tumor formation has also been proposed. There is now a great deal of interest in HIF targeting as a new cancer therapy option. Now, it is time to study the role of antioxidants in cancer hypoxia for cancer treatment.
Prof. Dr. Bonglee Kim
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Antioxidants is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- antioxidants
- hypoxia
- HIF1alpha
- HIF2alphfa
- metastasis
- cancer
- Natural products
- Botanical drugs
- Drug resistance
- Apoptosis
- microRNA
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
